Sound Pharmaceuticals is pleased to announce that the FDA has allowed its pivotal Phase 3 clinical protocol for SPI-1005 in the Treatment of Patients with Meniere’s Disease (STOPMD-3). Read More
The University of Oxford and Sound Pharmaceuticals (SPI), are pleased to announce the successful completion of a Phase 2a study testing SPI-1005 as a new treatment for bipolar disorder (BPD). Read More
SEATTLE — Sound Pharmaceuticals is pleased to announce that the FDA’s Division of Neurology Products has granted its request for Fast Track Designation (FTD) involving SPI-1005 in the treatment of Meniere’s Disease (MD).
SPI-1005 hits pre-specified endpoints resulting in a significant improvement in hearing loss of 65% and 95% relative to placebo